# Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

> **NCT02756962** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 107 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **PROCEDURE:** Allogeneic stem cell transplant
- **PROCEDURE:** Bone marrow aspiration
- **PROCEDURE:** Punch skin biopsy
- **DEVICE:** ClinSeq

## Key facts

- **NCT ID:** NCT02756962
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-06
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02756962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02756962, "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02756962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*